NRx Pharmaceuticals (NRXP) announced that it has licensed Real World Evidence, RWE, drawn from over 70,000 patients in the United States who were treated with either intravenous ketamine or nasal S-ketamine for depression and suicidal ideation. The information is being submitted in support of NRx’s application for Accelerated Approval of NRX-100 under Fast Track Designation for Treatment of Suicidal Ideation in Depression and Bipolar Depression. Currently, there is no medicine approved to treat suicidal ideation and the only FDA-approved treatment today is Electroshock Therapy.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/14/25
- Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/13/25
- Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/12/25
- Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/9/25
- Psychedelic: Bright Minds reports results from Phase 2 BMB-101 trial